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Abstract
Epstein-Barr virus (EBV) has been identified as a putative environmental trigger of multiple sclerosis (MS), yet EBV’s role in
MS remains elusive. We utilized murine gamma herpesvirus 68 (cHV-68), the murine homolog to EBV, to examine how
infection by a virus like EBV could enhance CNS autoimmunity. Mice latently infected with cHV-68 developed more severe
EAE including heightened paralysis and mortality. Similar to MS, cHV-68EAE mice developed lesions composed of CD4 and
CD8 T cells, macrophages and loss of myelin in the brain and spinal cord. Further, T cells from the CNS of cHV-68 EAE mice
were primarily Th1, producing heightened levels of IFN-c and T-bet accompanied by IL-17 suppression, whereas a Th17
response was observed in uninfected EAE mice. Clearly, cHV-68 latency polarizes the adaptive immune response, directs a
heightened CNS pathology following EAE induction reminiscent of human MS and portrays a novel mechanism by which
EBV likely influences MS and other autoimmune diseases.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the
central nervous system (CNS). In MS, the myelin sheath, that
insulates and protects neurons, is attacked and destroyed by the
host’s immune system leading to progressive disability [1]. MS is
considered to be the result of an environmental influence in
genetically susceptible individuals. Different environmental trig-
gers have been associated with MS development and viral
infections are the most common suspects [1–2].
To date, Epstein-Barr virus (EBV) has the strongest correlation
with MS development [2]. EBV is a DNA virus of the c-
herpesvirus family. It establishes a life-long latent infection mainly
in B cells [3], but it has been shown to have the ability to infect
other cell types such as epithelial cells, endothelial cells and
monocytes [4–5]. It infects 90% of the human population and it is
usually acquired during childhood. When primary infection takes
place during adolescence or in adulthood, it leads to infectious
mononucleosis [6]. All MS patients are EBV seropositive [7] and
individuals with a history of mononucleosis have a 20-fold higher
risk of developing MS later in life [2]. Moreover the EBV-specific
humoral and cellular immunity seems dysregulated in MS
patients: there is an increase in anti-EBV antibodies titer years
before MS onset [8], a decreased CD8+ EBV response [9] and the
presence of polyfunctional myelin/EBV cross-reactive CD4+ T
cells in MS patients [10]. Finally, although still controversial, EBV
infected B cells have been found in ectopic follicles in the brain of
MS patients [11–14]. Despite all this evidence, it is still not clear
how EBV would trigger CNS autoimmunity. Although EBV does
not infect rodents, murine gamma herpesvirus-68 (cHV-68) has
been a useful tool in studying the relationship between the immune
system and latent c-herpesvirus infection in mice [15].
Experimental autoimmune encephalomyelitis (EAE) is a well-
studied and accepted model for the study of MS in rodents [16].
After immunization with myelin peptides emulsified with adju-
vants, mice develop ascending paralysis and present with CD4 T
cell and macrophage infiltrations in the white matter of the spinal
cord, with minimal brain inflammation. In MS, however, the vast
majority of myelin lesions are found within the brain parenchyma
and equivalent numbers of CD8 T cells are found alongside with
CD4 T cells, both playing critical roles in the disease pathology
[1,17]. Despite these differences and others, EAE has proven to be
a valuable tool in the development of therapies that are now being
successfully used to treat MS [18].
Although cHV-68’s genome differs from EBV, it elicits an
immune response in mice that shares many features with EBV. In
fact both viruses establish a life long infection in B cells, deeply
modulating the immune response of the host, leading to the
expansion of a potent CD8 response similar to that detected in
humans during mononucleosis [19]. Because of these similarities,
we decided to test the impact of a cHV-68 latent infection during
the development of EAE. When induced for EAE, mice latently
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infected with cHV-68 showed a significantly modified disease
phenotype that recapitulated aspects of human MS not typically
observed in EAE. cHV-68 EAE mice presented with greater
ascending paralysis, more neurological symptoms, brain inflam-
mation with myelin lesions driven by a potent Th1 response and
CD8 T cell infiltrations.
Results
Latent infection with cHV-68 enhances EAE symptoms
without CNS infection or increased viral reactivation
To determine the impact of cHV-68 latency on the develop-
ment of EAE in mice, C57Bl/6 mice were infected with cHV-68
and allowed to recover for five weeks to enable complete clearance
of the acute infection and establishment of latency prior to EAE
induction. Viral clearance was demonstrated by absence of
plaques on viral plaque assays on spleens harvested on day 35
post infection. When tested, mice previously infected with cHV-68
presented with earlier onset of EAE (around day 7–8 post
induction), compared with naı̈ve mice induced for EAE that
developed paralysis around day 10–12 post EAE induction
(Figure 1A). Moreover cHV-68 EAE mice presented with worse
clinical EAE scores (Figure 1A) and this includes a heightened
mortality rate (15%) between day 12–18 post EAE induction
(Figure 1D). To demonstrate the specificity of the disease
phenotype to cHV-68 infection, EAE was induced in mice
previously infected with Lymphocytic Choriomeningitis virus
(LCMV). LCMV induces a strong well-characterized Th1
response as well as a strong memory CD8 T cell response similar
to cHV-68. Mice previously infected with LCMV (LCMV EAE),
showed a clinical disease course similar to uninfected EAE mice
(Figure 1B). At the dose given, LCMV does not establish a latent
or persistent infection, so to further test the cHV-68 specificity of
our phenotype, mice were infected with a b-herpesvirus (murine
cytomegalovirus, MCMV), capable of establishing a latent
infection similar to cHV-68. MCMV EAE mice developed EAE
with the same clinical disease course of uninfected EAE mice and
showed 100% survival after immunization (data not shown).
Additionally, EAE was induced in cHV-68 mice without
administering pertussis toxin (cHV-68 MOG CFA). Interestingly,
cHV-68 MOG CFA mice (Figure 1C, blue line) developed milder
paralysis than cHV-68 EAE mice, yet still displayed a disease
course similar to EAE alone (Figure 1C, black line). These data
clearly demonstrate that this phenotype is a feature specific for
cHV-68 latent infection as only latent cHV-68 infection confers
susceptibility to a more severe form of EAE that includes a
heightened level of mortality.
Previous work has demonstrated that reactivation of cHV-68 in
latently infected mice occurs following treatment with toll like
receptors (TLR) ligands such as poly I:C or LPS [20]. For EAE
induction, mice are injected with complete Freund’s adjuvant
(CFA) and pertussis toxin (PTX) which are constituted with TLR
ligands. To determine whether the increased EAE symptoms
observed were due to increased viral reactivation and replication,
limiting dilution assays were performed to allow for the
simultaneous quantification of ex-vivo cHV-68 reactivation
(Figure 2A) and pre-formed virus (Figure 2B). cHV-68 EAE mice
showed a similar extent of ex-vivo reactivation and similar amount
of pre-formed virus in the spleen both at day 7 and day 14 post
EAE induction when compared to cHV-68 infected mice (5–7
weeks post infection) without EAE induction. TLR ligands present
in the CFA are not reactivating more cHV-68 and enhanced EAE
scores are not due to increased viral replication.
To further confirm the lack of dependence on viral replication/
reactivation, EAE was also induced in uninfected IL-6KO mice
and in cHV-68 IL-6KO mice. IL-6KO mice are resistant to EAE
induction and both latently infected and uninfected mice retained
this resistance. Moreover, cHV-68 mice were treated with
cidofovir, a drug known to suppress cHV-68 replication [21],
before and after EAE induction. cHV-68 mice treated with
cidofovir showed no differences in phenotype and clinical disease
as compared to untreated cHV-68 mice (data not shown).
Finally, to ask whether virus replication was detectable in the
CNS, DNA was extracted from brains and spinal cords and the
presence of viral DNA was assessed using the most sensitive PCR
approach (nested PCR; Figure 2C). All brains and spinal cords
tested negative for cHV-68 DNA following EAE induction.
Overall these results indicate that the observed phenotype was
not the result of a reactivated replicating virus and that latent
cHV-68 infection is inducing greater disease through an indirect
mechanism.
cHV-68 EAE mice have increased CD8/CD4 T cells
infiltrations, increased inflammation and MS-like lesions
in the brain
Since in addition to severe ascending paralysis, cHV-68 EAE
mice also displayed unusual symptoms such as loss of balance,
ataxia and hunched posture; we investigated both spinal cord and
brain histopathology. During the course of EAE, mice develop
ascending paralysis due to spinal cord inflammation. Immune
infiltrations in the brain cortex are atypical and, if present, are
restricted to the meninges. To assess the composition and to
quantify infiltrating immune cells in cHV-68 EAE mice and in
EAE mice, CNS infiltrates were isolated and stained at day 14–16
post EAE induction (mean clinical score of 3 for cHV-68 EAE
mice, EAE mice were harvested at the same time). cHV-68 EAE
mice presented with an increased number of T cells in the CNS,
both in the brains and in the spinal cords when compared to EAE
mice (Figure 3A). CD4 T cells are the primary T cells type
infiltrating the CNS during EAE (Figure 3C). Surprisingly,
increased percentages of CD8 T cells were detected in both the
spinal cords and the brains of cHV-68 EAE mice (Figure 3B).
To confirm the FACS data and demonstrate that T cells in the
brain were infiltrating into the parenchyma and were not confined
to the meninges, immunohistochemistry on brain sections was
performed both at day 15 and day 28 post EAE induction. Figure 3
shows data from day 28, equivalent results were obtained at day 15
Author Summary
Multiple sclerosis (MS) is a chronic inflammatory disease of
the central nervous system (CNS) that leads to progressive
disability. The causes of the disease are still unknown. Viral
infections has been linked to MS development and
Epstein-Barr virus has been shown to have a strong link
to MS. Here, we use an animal model of MS, experimental
autoimmune encephalitis (EAE), to study how EBV can
trigger MS. Since EBV does not infect rodents, we infected
mice with murine gamma herpesvirus 68 (cHV-68), the
murine equivalent of EBV. We found that mice previously
infected with cHV-68 developed more severe EAE when
compared to uninfected EAE mice and showed patholog-
ical features that recapitulate human MS. cHV-68 EAE
presented with increased CD4 and CD8 T cells infiltrations
in the brain, increased brain inflammation and demyelin-
ation. This model provides new insight on how EBV might
be triggering MS, shedding light on the development of
the disease.
cHV-68 Elicits a Potent Th1 Response during EAE
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Figure 1. cHV-68 infected mice show worse EAE symptoms and increased mortality. Mice were infected with cHV-68 (dashed line) or
LCMV or MEM only (solid lines). Five weeks p.i. EAE was induced (day 0 on the graph) with (EAE) or without (MOG CFA) pertussis toxin. (A-B-C) EAE
scores up to day 28 post EAE induction (three separate experiments, n = 16/group). Data are shown as mean score. Data analyzed with two-way
ANOVA followed by Bonferroni’s post test; *** p,0.001; ** p,0.01 * p,0.05. (D) Survival up to day 18 post EAE induction (four-five separate
experiments, n = 28/group). Data analyzed with Kaplan-Meier analysis.
doi:10.1371/journal.ppat.1002715.g001
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post EAE. cHV-68 EAE mice (upper left panels) showed
heightened CD4 (Figure 3D) and CD8 (Figure 3E) T cell
infiltrations inside the brain parenchyma. Brain sections were also
stained for F4/80 that is expressed both on infiltrating macro-
phages and on activated microglia, indicating areas of inflamma-
tion in the CNS (Figure 3F). cHV-68 EAE mice showed
Figure 2. cHV-68 does not reactivate more upon EAE induction and does not infect the CNS. Mice were infected with cHV-68. Five weeks
p.i., EAE was induced (red line with triangles, black bar) or not induced (black line with squares, open bar). At day 7 (left panel) and day 14 (right
panel) post EAE induction, spleens were harvested and a limiting dilution assay was performed using (A) live splenocytes to assess the amount of ex-
vivo viral reactivation and (B) lysed splenocytes to assess the amount of pre-formed virus (three separate experiments using 3–4 mice/group) (C)
Brain and spinal cords were harvested from perfused cHV-68 EAE mice at different timepoints pre and post EAE (day 0 before EAE induction; day 3;
day 7 and day 14 post EAE). DNA was extracted and a nested PCR was performed to detect cHV-68 DNA. A spleen was used as a positive control.
Figure C shows a representative gel of three separate experiments (15 brains/spinal cords harvested at day 14 post EAE induction have been loaded
on the gel displayed here; 37 brains and 39 spinal cords were analyzed in total).
doi:10.1371/journal.ppat.1002715.g002
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heightened staining in multiple areas of the brain. Conversely, the
brains from EAE mice (bottom left panels) showed fewer
infiltrating CD4 T cells, mostly lining the blood vessels and the
meninges, no CD8 infiltrations and weaker F4/80 staining when
compared to brains from cHV-68 EAE mice. Additionally, EAE
was induced in cHV-68 mice without administering pertussis toxin
(cHV-68 MOG CFA). Pertussis toxin has been shown to be
important both as an adjuvant to prime the MOG specific
response and to permeabilize the blood-brain barrier [22]. cHV-
68 MOG CFA mice develop milder paralysis than cHV-68 EAE
mice but still showed T cells infiltrations into the brain
parenchyma and inflammation (Figure 3D–F, upper right panels).
Further, LCMV EAE mice did not display any observable
lymphocyte infiltrations in the brain and had an EAE course
equal to that observed in uninfected mice (Figure 3D–F, bottom
right panels). Spinal cords were analyzed at the same time points
as brains. Hematoxylin and eosin staining showed increased
amounts of immune cells infiltrating in the spinal cords of cHV-68
EAE mice, thus confirming the FACS data (Figure S1). Finally and
most importantly, the development of lesions in the brain
parenchyma similar to MS were observed in cHV-68 EAE mice
with localization of infiltrating CD4/CD8 T cells and increased
Figure 3. cHV-68 EAE mice show increased amount of CD8 T cells infiltrations in the CNS and inflammation inside the brain
parenchyma. Mice were infected with cHV-68 (black bars) or MEM only (open bars). Five weeks p.i. EAE was induced. (A-B-C) At day 14–16 post EAE
induction (mean clinical score of 3 for cHV-68 EAE mice, EAE mice were harvested at the same time), mice were perfused, brains (right panels) and
spinal cords (left panels) were harvested and processed to isolate immune infiltrates. (A) Total number of infiltrating T cells (CD45+ CD11b2). (B)
Percentage of infiltrating CD3+ CD8+ lymphocytes and (C) CD3+ CD4+ lymphocytes. Three separate experiments with 8–6 mice/group; data were
analyzed with t-test: *** p,0.001; ** p,0.01, * p,0.05. (D-E-F) Mice were infected with cHV-68 (upper panels left and right: cHV-68 EAE and cHV-68
MOG CFA); or LCMV (bottom right panel: LCMV EAE) or MEM only (bottom left panel, EAE). Five weeks p.i. EAE was induced with or without (MOG
CFA) pertussis toxin. At day 28 post EAE induction (similar results obtained at day 15 post EAE induction), mice were perfused and brains were
embedded in OCT, snap frozen, cut and stained with antibodies specific for CD4 (D), CD8 (E) and F4/80 (F). The pictures are representative of three
separate experiments (n = 16/group). Scale bar: 100 mm.
doi:10.1371/journal.ppat.1002715.g003
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inflammation (F4/80 staining) on consecutive sections (Figure 4).
Similar to MS, multiple pronounced yet small lesions of
mononuclear cells with areas of myelin loss were observed within
the white matter of both the cerebellum (Figure 4) and corpus
callosum. This demonstrates that cHV-68 latent infection leads to
strong T cell activation post EAE induction with infiltration inside
the white matter of the brain leading to myelin damage.
CD8 T cells infiltrating in the CNS of cHV-68 EAE mice
express granzyme B and are specific for viral proteins
CD8 infiltrations, usually not present in the CNS of EAE mice,
were detected in the brain and spinal cords of cHV-68 EAE mice
in significantly higher percentages (Figure 3 and Figure 5A). CD8
T cells were further characterized for granzyme B production that
has the potential to damage oligodendrocytes [23]. cHV-68 EAE
mice presented with higher levels of CD8+ Granzyme B+ T cells
in both the brain and the spinal cords (Figure 5B).
As it was possible that cHV-68 specific memory CD8 T cells
could become bystander activated upon EAE induction and driven
into the site of inflammation in the CNS, the specificity of the CD8
in cHV-68 EAE mice was investigated. A percentage of CD8 T
cells infiltrating in both the brains (4.960.5%) and the spinal cords
(3.460.5%) of cHV-68 EAE mice (Figure 5C) were specific for the
two predominant viral epitopes (p56 and p79). The first epitope is
from ORF 6 (p56) that encodes a single stranded DNA binding
protein. The second epitope is from ORF 61 (p79) that encodes
the large ribonucleotide reductase subunit [24]. Both are
expressed during cHV-68 acute infection. The percentages of
p56 and p79 specific CD8 T cells detected in the CNS post EAE
(49 days postinfection) were equivalent to their respective
percentages in spleens (4.363.2%) of cHV-68 infected mice at
day 40 post primary infection (Figure 5C, upper right panel);
consistent with previously published results [24]. These results
demonstrate that infiltrating CD8 T cells expressing granzyme B
Figure 4. cHV-68 EAE mice show MS-like lesions in the white matter of the cerebellum and in the corpus callosum. Mice were infected
with cHV-68 or MEM only. Five weeks p.i. EAE was induced. At day 28 post EAE induction mice were perfused and brains were embedded in OCT,
snap frozen, cut and stained with antibodies specific for CD4, CD8 and F4/80; or were formalin fixed and embedded in paraffin and stained with luxol
fast blue. (A–B) The images displayed for CD4-CD8-F4/80 staining are consecutive sections cut from the same cerebral hemisphere of the same
mouse (all images from cHV-68 EAE mice). Scale bar: 50 mm. (C) The arrows show an area of demyelination in the cerebellum of a cHV-68 EAE mouse
and the asterisks highlight immune cell infiltrations. The right panel shows a normal cerebellum from a naı̈ve EAE mouse. Scale bar: 100 mm. All
pictures are representative of two separate experiments (n = 16/group).
doi:10.1371/journal.ppat.1002715.g004
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Figure 5. CD8 T cells infiltrating in the CNS of cHV-68 EAE mice express granzyme B and are specific for viral proteins. Mice were
infected with cHV-68 or MEM only. Five weeks p.i. EAE was induced. At day 14–16 post EAE induction (mean clinical score of 3 for cHV-68 EAE mice,
EAE mice were harvested at the same time), mice were perfused, brains and spinal cords were harvested and processed to isolate immune infiltrates.
cHV-68 Elicits a Potent Th1 Response during EAE
PLoS Pathogens | www.plospathogens.org 7 May 2012 | Volume 8 | Issue 5 | e1002715
in cHV-68 EAE mice provide a considerable potential for CNS
pathology. Moreover, as the size of the population of the virus
specific CD8 T cells found in the CNS post EAE was similar to
that observed in other organs during latency and typical for
latently infected mice 40 days post acute infection, their migration
into the CNS is likely due to ordinary activation typically observed
following a non-specific environmental insult.
T cells infiltrating the CNS of cHV-68 EAE mice produce
higher amounts of IFN-c and T-bet along with IL-17
downregulation
To determine the cytokines produced by the T helper response
after EAE immunization, T cells were isolated from the CNS and
restimulated ex-vivo (Figure 6). The T cell response primed upon
EAE induction in naı̈ve mice is a mixed Th1-Th17 CD4 T cell
response with production of both IFN-c and IL-17 primarily in
spinal cords [25]. In contrast, in cHV-68 EAE mice, CD4 T cells
produced significantly increased amounts of IFN-c (Figure 6A),
particularly within the brain parenchyma, along with suppressed
levels of IL-17 (Figure 6C). Moreover increased percentages of
these CNS CD8 T cells from cHV-68 EAE mice produced IFN-c
(Figure 6B). As expected, the amount of CD8 T cells infiltrating
the CNS of naı̈ve EAE mice was too low to perform the assay.
When restimulated with the MOG specific peptide, similar results
were observed with T cells from the CNS (Figure S2). These
results indicate that, upon EAE induction in cHV-68 mice, the T
helper response was skewed towards a Th1 phenotype, whereas
the Th17 response was suppressed.
Additionally, infiltrating T cells were stained for T-bet and
ROR-ct (Figure 6D). In cHV-68 EAE mice, T-bet was
significantly upregulated in all the CNS infiltrating T cells
compared to EAE mice. Strikingly, in cHV-68 EAE mice, T cells
not producing IFN-c (Figure 6D, upper panels) still showed T-bet
upregulation. Conversely, ROR-ct was upregulated only in IL-17
secreting T cells and the levels were comparable between EAE and
cHV-68 EAE mice (Figure 6D). Finally, cHV-68 T cells, in the
periphery, exhibited an effector memory phenotype with increased
expression of CD44 and downregulation of CD62L, when
compared to T cells from naı̈ve mice either before or after EAE
induction (data not shown). This demonstrates that mice latently
infected with cHV-68 skew a more potent Th1 response upon
immunization with suppression of the classical EAE Th17
response.
cHV-68 EAE mice have increased levels of pro-
inflammatory cytokines in the serum and a decreased
anti-MOG IgG1/IgG2a ratio
Since cHV-68 EAE mice showed a strong Th1 response, the
level of Th1 cytokines in the serum was measured. Sera was
harvested at different time points post EAE induction and the
following cytokines and chemokines were analyzed: IFN-c, IL-
12p70, TNF-a, IL-6, IL-10, IL-17A, GM-CSF, G-CSF, MCP-1
(CCL2), MIP-1a (CCL-3), MIP-1b (CCL-4), MIG (CXCL-9) and
RANTES (CCL-5). IFN-c and TNF-a were significantly increased
in the serum of cHV-68 EAE mice, when compared to EAE mice,
at day 10, 15 and 28 post EAE induction (Figure 7A shows results
for day 28, similar results were obtained at day 10 and 15 post
EAE, as shown in Figure S3). On the other hand, the chemokines
RANTES (CCL-5) and MIG (CXCL-9) were statistically signif-
icant different only at day 10 post EAE induction, when mice
started to develop symptoms (Figure 7B). All the remaining
cytokines tested and listed above were not differentially expressed
between the sera of the two mouse groups. Levels of cytokines and
chemokines were also analyzed in the supernatants obtained from
brain and spinal cords homogenates (see Materials and Methods
for CNS supernatant preparation). At day 14–16 post EAE
induction, MCP-1 was detected in the brains and spinal cords of
both EAE and cHV-68 EAE mice at similar levels. Increased
levels of IFN-c were detected in the brains and spinal cords of
cHV-68 EAE mice when compared to EAE mice (Figure S4). All
the remaining cytokines analyzed in the CNS were below the
detection limit. Considering the importance of type I interferons in
controlling acute cHV-68 infection [26], the levels of IFN-b in the
sera were also tested. IFN-b was detected at a similar level in the
sera of both cHV-68 EAE mice and uninfected EAE mice (data
not shown).
Since CCL-5 and CXCL-9 were found to be upregulated in the
sera of cHV-68 EAE mice, the levels of their respective chemokine
receptors (CCR5 for CCL-5 and CXCR3 for CXCL-9) were
analyzed at day 15 post EAE induction in the spleen. No difference
was detected in the expression of CCR5 in both CD4 and CD8 T
cells. On the other hand, greater numbers of CD4 and CD8 T cells
from cHV-68 EAE mice expressed CXCR3, compared to cells
from uninfected EAE mice (Figure S5).
These results show that the Th1 response triggered by EAE
induction in cHV-68 EAE mice is sustained even at later time points
post immunization and high levels of IFN-c and TNF-a are likely
responsible of perpetuating this Th1 response. Moreover, as
RANTES and MIG control leukocyte adhesion and migration into
the target tissue [27], their upregulation at day 10 post EAE,
coincident with the upregulation of CXCR3 on T cells, is likely
responsible for the increased T cell infiltration in cHV-68 EAE mice.
Since cHV-68 infects B cells and B cells infiltrating the CNS
were not detected (results confirmed by both FACS analysis of
CNS infiltrates and immunohistochemistry at day 15 and 28 post
EAE using anti-CD19 antibodies), the hypothesis that the viral
infection could precipitate EAE by increasing the production of
anti-MOG autoantibodies was investigated. Sera harvested at day
28 was tested for the presence of both MOG-specific and brain-
extract specific IgGs (Figure 7c). There was no difference in the
amount of anti-MOG IgG but there was an increase in the
amount of anti-brain extract antibody in cHV-68 EAE mice. This
indicates that MOG autoantibodies are not likely playing a role in
the increased clinical score of cHV-68 EAE mice and the
increased presence of brain-extract specific antibodies are likely
due to epitope spreading to CNS proteins due to increased CNS
inflammation in cHV-68 EAE mice. Since anti-MOG IgGs were
not different between infected and uninfected mice, differences in
IgG isotype were tested. cHV-68 EAE mice showed a decreased
anti-MOG IgG1/IgG2a ratio (Figure 7D). This is consistent with
the high concentrations of IFN-c detected in the serum that are
likely inhibiting isotype switching towards IgG1 [28], thus
(A) Representative FACS plots showing the percentages of CD8 T cells infiltrating in the spinal cords (similar results were obtained in the brains) and
histogram (B) showing the number of CD8+ granzyme B+ T cells infiltrating in the spinal cords and in the brains (immune cells were not restimulated
before granzyme B staining). Two separate experiments with 6 mice/group, data analyzed with t-test. (C) Representative FACS plots showing
percentages of CD8+ T cells with TCR specific for cHV-68 epitopes (p56 and p79) in the spleen of EAE mice (negative control); in the spleen of cHV-68
EAE mice (positive control; 3.361.6%), in the spinal cord (3.460.5%) and in the brain (4.960.5%) of cHV-68 EAE mice. Two separate experiments with
6 mice/group, errors are s.d.
doi:10.1371/journal.ppat.1002715.g005
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confirming the presence of a strong Th1 response in cHV-68 EAE
mice.
CD11b+ CD11c+ cells from cHV-68 EAE mice are able to
prime an enhanced Th1 response both in vitro and in vivo
Collectively our results indicate that cHV-68 EAE mice are
polarizing a distinct T helper response post MOG immunization in
comparison with typical EAE. We hypothesized that a subset of
antigen-presenting cells, as a result of a direct infection or under the
influence of other signals received by other immune cells during the
infection, were able to skew a Th1 phenotype upon MOG
presentation. The levels of different cytokines produced by B cells,
CD11b+ and CD11c+ cells were assessed during the antigen
presentation phase of EAE (day 4). In cHV-68 EAE mice, CD11b+
CD11c+ cells produced IFN-c at day 4 post EAE (7–8%);
conversely, CD11b+CD11c+ cells from uninfected EAE mice
produced less IFN-c (3–4%). To test the ability of these antigen-
presenting cells to prime a Th1 phenotype during MOG
presentation, T cells from 2D2 T cell receptor (TCR) transgenic
mice, that express a MOG- specific TCR, were isolated and
incubated with MOG peptide and CD11b+ CD11c+ cells isolated
either from an uninfected EAE mouse or a cHV-68 EAE mouse at
day 4 post EAE induction. cHV-68 EAE CD11b+ CD11c+ cells
induced an increased production of IFN-c in these MOG specific
transgenic T cells (Figure 8A–B), while IL-17 was not detectable.
Further, a nested PCR on CD11b+ CD11c+ cells isolated from
cHV-68 mice did not find any cHV-68 DNA, indicating that the
ability of these antigen-presenting cells to prime a Th1 response was
not dependent on direct cHV-68 infection or replication.
Additionally, the expression levels of co-stimulatory molecules and
MHC class I- II on CD11b+ CD11c+ cells were analyzed at day 4
post EAE induction. Splenic CD11b+CD11c+ cells isolated from
cHV-68 EAE mice expressed higher levels of CD40 and MHC I -II
when compared to EAE mice (Figure 8C), whereas the levels of
CD80 and CD86 were similar between the two groups. Finally, to
assess if these CD11b+CD11c+ cells were able to prime a stronger
Th1 response also in vivo, CD11b+CD11c+ cells isolated from
either cHV-68 EAE mice or EAE mice were adoptively transferred
into naı̈ve mice and 24 hours later EAE was induced. Mice
transferred with cHV-68 EAE CD11b+CD11c+ cells presented
with increased percentages of infiltrating CD4+ IFN-c+ T cells into
the CNS and decreased percentages of CD4+ IL-17+ T cells
(Figure 8D shows data obtained from the spinal cords, a similar
trend was observed in the brains). These results indicate that a
subset of CD11b+ CD11c+ antigen-presenting cells found in cHV-
68 EAE mice, without being directly infected by the virus, induced
the production of increased levels of IFN-c in T cells both in vivo
and in vitro. This cell subset is likely responsible for the polarization
of the potent Th1 response that is observed in cHV-68 EAE mice.
Discussion
The study of the ‘‘viral etiology of MS’’ has been challenging
because of the absence of a mouse model that could be exploited
to dissect the relationship between candidate MS viruses and
development of CNS autoimmunity. EBV has been strongly linked
to MS development even if the mechanisms by which EBV
triggers autoimmunity are not understood [29]. We demonstrated
that a latent infection with a gamma herpesvirus changes the
polarization of the myelin specific T cell response after EAE
induction leading to a potent Th1 response with more severe
paralysis, atypical neurological symptoms, different composition
and localization of the CNS infiltrates and myelin lesions in the
white matter reminiscent of human MS.
Brain inflammation accompanied by T cell infiltrations within
the brain parenchyma is rarely detected in EAE, although it is a
critical characteristic of human MS [1]. Further, during EAE,
CD4 T cells are the predominant T cell type to invade the CNS,
whereas in humans, CD8 T cells are equally present in the MS
plaques [1,17]. In cHV-68 EAE mice, CD8+ IFN-c+ granzyme+
cells are infiltrating the brain parenchyma and a minority of these
is specific for cHV-68 proteins. Thus, activated CD8 T cells that
are not specific for CNS epitopes are able to enter the brain
parenchyma and likely participate in sustaining a pro-inflamma-
tory loop that recruits additional immune cells. These findings are
similar to those recently shown by Matullo et al. in which a
polymicrobial challenge leads to the recruitment of LCMV specific
T cells in the CNS despite the absence of LCMV infection in the
CNS [30]. We suggest that our model could potentially be used to
study the behavior of CD8 T cells in CNS autoimmunity and
elucidate the signals that guide CD8 infiltrations inside the brain
during demyelinating diseases.
It has long been described that MS patients have a potent CNS
Th1 response [31–32]. The potent Th1 response observed in
cHV-68 EAE mice not only includes higher amounts of IFN-c but
also an upregulation of T-bet in all T cells, including those not
actively producing any cytokines. Interestingly T cells from MS
patients exhibit preferentially a Th1 phenotype [31–32], T-bet
levels are predictive of IFN-b therapy efficacy in MS patients [33]
and T-bet is upregulated in patients with active disease and is
downregulated during remission [34].
Our data demonstrate that, upon MOG peptide presentation,
CD11b+CD11c+ from cHV-68 EAE mice are able to induce,
both ex vivo and in vivo, an increased production of IFN- c in T
cells with a suppression of the Th17 response. Intriguingly,
CD11b+CD11c+ from cHV-68 EAE mice have increased
expression of MHC class I and II as well as CD40. It has been
shown that the strength of signal upon antigen presentation
dictates the fate of the T helper response [35]. A weaker signal
preferentially primes a Th17 response. Thus, increased expression
of MHC II and CD40 on the surface of CD11b+CD11c+ cells
likely provides a strong activation signal and is likely responsible
for the suppression of the Th17 response and the skewing towards
the observed Th1 phenotype found in cHV-68 EAE mice. CD11b
is found mainly on the surface of monocytes/macrophages, but it
can also be co-expressed, along with CD11c, on the surface of
dendritic cells and NK cells [36–37]. Moreover, IFN-c is mainly
produced by T cells and NK cells but also macrophages [38] and
Figure 6. cHV-68 EAE mice show increased T cell expression of IFN-c and T-bet, accompanied by IL-17 suppression. Mice were
infected with cHV-68 (black bars, shaded histograms) or MEM only (open bars, open histograms). Five weeks p.i. EAE was induced. At day 14–16 post
EAE induction (mean clinical score of 3 for cHV-68 EAE mice, EAE mice were harvested at the same time), mice were perfused, brains (left panels) and
spinal cords (right panels) were harvested and processed to isolate immune infiltrates that were restimulated ex-vivo with PMA and ionomycin before
performing FACS intra cellular staining. (A) Percentages of infiltrating CD3+ CD4+ IFN-c+ lymphocytes. (B) Percentage of infiltrating CD3+ CD8+ IFN-c
lymphocytes (EAE CD8 infiltrations were not enough to perform FACS). (C) CD3+ CD4+ IL-17+ lymphocytes. Three separate experiments with 8-6
mice/group. Data were analyzed with t-test: ** p,0.01, * p,0.05. (D) T-bet and ROR-ct levels in CD3+ CD4+ IFN-c6 IL-176 lymphocytes in the spinal
cords (similar results obtained from the brains) of cHV-68 EAE mice (grey shaded histograms) or EAE mice (open histograms). Representative
histograms of two separate experiments with 6–8 mice/group.
doi:10.1371/journal.ppat.1002715.g006
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Figure 7. cHV-68 EAE mice show increased levels of pro-inflammatory cytokines and chemokines and a decreased anti-MOG IgG1/
IgG2a ratio in the serum. Mice were infected i.p. with cHV-68 (black bars) or MEM only (open bars). Five weeks p.i., EAE was induced. At day 10, 15
and 28 post EAE induction blood was harvested through a cardiac puncture and the levels of different (A) cytokines (day 28 shown here) and (B)
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dendritic cells [39] have been shown to produce IFN-c in response
to both endogenous and exogenous stimuli. Interestingly, cHV-68
activates macrophages and this phenotype protects mice from
lethal infections by another intracellular pathogen, Listeria [40].
This mechanism is independent from T cells but dependent on
IFN-c, showing that a latent infection with cHV-68 was conferring
a broad innate cross protection that did not require IFN-c
produced by memory T cells. In our model, it is possible that
macrophages and/or dendritic cells with an activated phenotype
that are secreting more pro-inflammatory Th1 skewing cytokines
are responsible for the priming of the potent Th1 response in
cHV-68 EAE mice.
Lastly and significantly, the ability to discover EBV in the brains
of MS patients has been controversial [11–14]. In the cHV-68
EAE mouse model, cHV-68 is no longer detectable in the CNS
tissue (by PCR) during disease and yet, it is indirectly influencing
the autoimmune response and immune cell polarization. It is easy
to imagine that EBV may well be acting similarly as the first
trigger of the second hit hypothesis. It is intriguing that mice
latently infected with the murine homologue of EBV are
developing an EAE that is more reminiscent of human MS. From
this model, experiments can be designed to ask how cHV-68 is
acting to allow T cells to preferentially enter the brain during MS,
specifically addressing the signals that are required and where they
arise.
In conclusion, we propose that EBV latent infection in patients
is influencing the development of disease following a second hit. In
this case, EAE induction results in a stronger disease as the result
of polarization of the adaptive T cell response. In MS patients, a
second trigger also leads to the skewing of the immune system
towards a Th1 biased phenotype and an increased activation
status resulting in MS lesions. As such, a patient’s history of
infection and, specifically, EBV latent infection are as important as




All animal work was performed under strict accordance with the
recommendations of the Canadian Council for Animal Care. The
protocol was approved by the Animal Care Committee (ACC) of
the University of British Columbia (certificate numbers: A08-0415
and A08-0622).
Infections and EAE induction
C57Bl/6 mice and 2D2 mice were purchased from the Jackson
Laboratory and were bred and maintained in our rodent facility at
the University of British Columbia. Mice were infected intraper-
itoneally (i.p.) between 7–10 weeks of age with 104 pfu of cHV-68
WUMS strain (purchased from ATCC, propagated on BHK cells);
or 104 pfu of LCMV Armstrong strain 53b (originally acquired
from Dr. M.B. Oldstone, propagated on BHK cells); or 2,500 pfu
of MCMV (from ATCC, generous gift of Dr. S.M. Vidal); or
200 ml of MEM as a control. Cidofovir (Vistide; Gilead Sciences)
was diluted in PBS and filter sterilized. It was administered
subcutaneously in the scruff of the neck at a dose of 25 mg/kg or
15 mg/kg as previous reports [21,41]. Mice were given a two days
loading dose four weeks post cHV-68 infection and 10 days before
EAE induction. After, mice were injected every 3rd day until day
15 post EAE induction when they were euthanized. EAE was
induced 35–40 days post infection by injecting subcutaneously
each mouse with 100 ml of emulsified complete Freund’s adjuvant
(DIFCO) with 200 mg of MOG 35–55 (GenWay biotech, purity
.95%) and 400 mg of dessicated Mycobacterium tuberculosis
H37ra (DIFCO). Mice also received two i.p. injections with
200 ng of pertussis toxin (List Biologicals) at time of immunization
and 48 hours later. Mice were scored on a scale of 0 to 5: 0, no
clinical signs; 0.5, partially limp tail; 1, paralyzed tail; 2 loss of
coordinated movements; 2.5; one hind limb paralyzed; 3, both
hinds limbs paralyzed; 3.5, hind limbs paralyzed, weakness in the
forelimbs; 4, forelimbs paralyzed; 5, moribund or dead.
Limiting dilution assay
At indicated time points post EAE, mice were euthanized and
spleen harvested. A single cell suspension was generated after RBC
lysis. A limiting dilution assay was performed, as previously
described [42], to analyze the amount of ex-vivo reactivation
(using live splenocytes) and the amount of pre-formed virus (using
lysed splenocytes through one cycle of freeze-thaw). Splenocytes
were plated on a 96 well plate on a monolayer of mouse
embryonic fibroblasts (MEF). Twelve 2-fold serial dilutions were
prepared starting at 105 cells/well. Twelve wells were plated for
each dilution. Plates were incubated at 37uC for 15–20 days and
then scored for cytopathic effect.
Nested PCR
DNA was extracted from brains, spinal cords and spleens of
perfused mice at indicated time points before and post EAE
induction using QIAamp DNA mini kit (QIAGEN) following
manufacture’s instruction. A nested PCR to detect cHV-68 was
performed as previously described [43]. Briefly, 2 ml of DNA were
added to a PCR mix composed of 0.2 mM dNTPs, 0.4 mM
primers and 2.5 U of Taq polymerase. The PCR cycles were the
following: 95uC for 2 min, followed by 20 cycles at 95uC for
1 min, 63uC for 1 min and 72uC for 1 min followed by 7 minutes
at 72uC. The primer used were 59 CCA TCT AGC GGT GCA
ACA TTT TCA TTA C 39 (forward) and 59 TTT ACT GGG
TCA TCC TCT TGT TTG GG 39 (reverse). Then, 2.5 ml from
the previous PCR reaction were used for the second PCR reaction
using the following internal primers with the same cycles: 59 CGA
ACA ACA ATC CCA CTA CAA TTA TGC G 39(forward) and
59 GTA TCT GAT GTG TCA GCA GGA GCG TC 39 (reverse).
The samples were run on a 2% agarose gels (Invitrogen) and the
462 bp expected band was visualized using SYBR safe (Invitrogen).
Immune cells isolation, staining and flow cytometry
At day 14–16 post EAE induction (mean clinical score of 3 for
cHV-68 EAE mice), mice were perfused with 30cc of PBS and
spinal cords, brains, spleens, inguinal and cervical lymph nodes
were isolated at indicated time points post EAE induction. A single
cell suspension was generated from all the organs. Immune cells
were further isolated from the CNS using a 30% Percoll gradient.
For intracellular staining, CNS mononuclear cells, splenocytes and
chemokines (day 10 shown here) were evaluated using BD Cytometric Bead Array kits. Data from day 28 are shown for both IFN-c and TNF-a; similar
results were obtained at day 10 and 15 post EAE induction. Three-two separate experiments for each time point with 3–6 mice/group. Data were
analyzed with t-test: *** p,0.001; ** p,0.01, * p,0.05. (C–D) Serum was harvested at day 28 post EAE and the levels of (C) total anti-MOG IgG (left
panel), total anti-brain extract IgG (right panel) and (D) anti-MOG IgG1 and IgG2a were quantified through ELISA. Two separate experiments with 8
mice/group. Data were analyzed with t-test: ** p,0.01; and Mann-Whitney U test: * p,0.05.
doi:10.1371/journal.ppat.1002715.g007
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Figure 8. CD11b+ CD11c+ cells from cHV-68 EAE mice are able to prime an enhanced Th1 response both in vitro and in vivo. Mice
were infected with cHV-68 or MEM only. Five weeks p.i., EAE was induced. At day 4 post EAE induction, spleens and lymph nodes were harvested and
CD11b+CD11c+ cells were isolated. CD4 T cells from 2D2 mice were isolated at the same time. CD11b+CD11c+ were incubated with 2D2 CD4 T cells
and different concentrations of MOG peptide for 72 hours. T cells were restimulated and stained to assess the production of IFN-c (A) Representative
FACS plot showing IFN-c production in 2D2 CD4 T cells after incubation with CD11b+CD11c+ cells isolated from a cHV-68 EAE mouse (upper right
panel) or a naı̈ve EAE mouse (upper left panel) and MOG peptide (100 mM). Lowers panels show the negative controls with/without MOG and with/
without restimulation. (B) Histograms showing the percentages of 2D2 CD4 T cells producing IFN-c after incubation with CD11b+CD11c+ cells from a
cHV-68 EAE mouse (black bars) or a naı̈ve EAE mouse (open bars) and 10 mM (left panel) or 100 mM (right panel) MOG peptide. Three separate
experiments with triplicate wells for each group. Data were analyzed with t-test: *** p,0.001. (C) Levels of MHC II, MHC I and CD40 expressed on
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lymph nodes cells were stimulated for 4 hours in IMDM (Gibco)
containing 10% FBS (Gibco), GolgiPlug (BD Biosciences), 10 ng/
ml PMA and 500 ng/ml ionomycin; or for 24 hours with MOG
peptide (100 mM) with addition of GolgiPlug during the last
5 hours of incubation. Cells were then incubated with Fc block
(BD Biosciences) on ice for 15 minutes. Antibodies for the cell
surface markers were added to the cells in PBS with 2% FBS for
30 min on ice. After wash, cells were resuspended in Fix/Perm
buffer (eBiosciences) for 30–45 min on ice, washed twice and
incubated with Abs for intracellular antigens (cytokines and
transcription factors) in Perm buffer (30 min, on ice). Fluorescently
conjugated antibodies directed against CD11b (clone M1/70),
CD11c (clone N418), CD4 (clone RM4-5), CD8 (clone 53-6.7),
CD19 (clone eBio1D3), CD3 (clone eBio500A2), CD45 (clone 30-
F11), CD44 (clone IM7), CD62L (clone MEL-14), CD80 (clone
16-10A1), CD86 (clone GL1), CD40 (clone 1C10), MHC I (clone
28-14-8), MHC II (clone M5), IL-6 (clone MP5-20F3), IL-10
(clone JES5-16E3), IL-17 (eBio17B7), IFN-c (clone XMG1.2),
TNF-a (clone MP6-XT22), T-bet (clone eBio4B10), ROR-ct
(clone AFKJS-9), granzyme B (clone 16G6) were all purchased
from eBiosciences. Anti IL-12 antibody (clone C15.6) was
purchased from BD Biosciences. Anti-CCR5 (clone HM-CCR5)
and CXCR3 antibodies (clone CXCR3-173) were purchased from
Biolegend. Samples were acquired using a FACS LSR II (BD
Biosciences) and analyzed using FlowJo software (Tree Star, Inc).
Tetramer staining
Immune cells were isolated as detailed above. One million cells
were incubated with a mixture of two class I tetramers, both
conjugated with APC (provided by the Trudeau Institute
Molecular Biology Core Facility). Tetramer p56 (Db/ORF6487–495
AGPHNDMEI) was diluted 1:300 and tetramer p79 (Kb/
ORF61524–531 TSINFVKI) was diluted 1:400. Cells were incubated
for 1 hour at RT and then washed. Surface staining was then
performed and cells were fixed in 1% PFA for 20 min on ice before
acquisition.
Histology and immunohistochemistry
Spinal cords harvested from perfused mice were formalin fixed
and paraffin embedded. Six-micron thick sections were stained
with eosin and hematoxylin or luxol fast blue (all from Sigma)
following standard protocols. Brains from perfused mice were
frozen in OCT (Fisher Scientific) and ten-micron thick sections
were processed for immunohistochemistry. Briefly, sections were
fixed in ice cold 95% ethanol for 15 min and washed in PBS
several times. This was followed by washes in TBS with 0.1%
Tween (TBST) and incubation for 10 min with 3% H2O2 to block
endogenous peroxidase. After washing, blocking buffer was added
for 1 h (10% normal goat serum in PBS). Primary antibody was
added overnight at 4uC: purified rat anti-mouse CD4, anti-mouse
CD8 and anti-mouse F4/80 (all from eBiosciences), diluted 1:100
in PBS 2% normal goat serum. After washes in TBST, the
biotinylated secondary antibody (anti-rat IgG, mouse absorbed,
Vector) was added for 1 h, diluted 1:200 in PBS 2% normal goat
serum. After washes in TBST, the Vectastain ABC reagent was
used (Vector) following manufacturer’s instruction. Then, DAB
(Sigma) was added as a substrate and, after incubation for 8 min in
the dark and several washes in distilled water, sections were
counterstained with Harris hematoxylin for 20 seconds, in lithium
carbonate for 30 sec, washed in several changes of distilled water
and mount with VectaMount AQ (Vector). Images were acquired
at RT using an Olympus BX61 microscope (46–206UPLSAPO
objective lenses) equipped with an Olympus DP72 digital camera,
using the CellSens dimension software.
Cytokines and chemokines analysis
Serum cytokine and chemokine levels were measured at the
indicated timepoints using a mouse inflammation CBA kit (BD
Bioscience) for detection of IL-6, IL-10, MCP-1, IFN-c, TNF-a
and IL-12p70 or a cytokine flex set (BD Bioscience) allow for
detection of CXCL-9 (MIG), CCL-3 (MIP-1a), CCL-4 (MIP-1b),
CCL-5 (RANTES), IL-17A, GM-CSF and G-CSF. Samples were
prepared according to manufacturer’s instructions and analyzed
on a BDFacsArray equipped with FCAP software (BD Bioscienc-
es). Serum levels of IFN-b were measured using a VeriKine Mouse
interferon beta kit (PBL interferon source) according to manufac-
turer’s instructions. For CNS supernatant analysis, brains and
spinal cords were homogenized in 10 mls of FACS buffer to obtain
a single cell suspension. The suspension was then centrifuged for
10 min at 1200 rpm. A total of 10 mls of CNS supernatant was
obtained for each sample, 1 ml was frozen at 280uC and then
50 ml were analyzed using the mouse inflammation CBA kit as
detailed above.
Auto-antibodies ELISA
Nunc immunoplate were coated with 10 mg/ml of MOG
peptide or 10 mg/ml of brain extract (purchased from Santa Cruz
Biotechnology) in carbonate buffer and incubated overnight at
4uC. Plates were washed three times with wash buffer (PBS, 0.05%
Tween). Blocking buffer (PBS with 1% BSA; 0.05% Tween and
10% FBS) was added in each well for 1 h. After removal of the
blocking buffer, day 28 post EAE induction sera samples diluted
1:20 and 1:40 in blocking buffer were added for 1.5 h at RT. After
washing, anti-mouse IgG-HRP (Sigma), diluted 1:1000 in blocking
buffer, was added for 1 h. After washing, OPD (0.2 mg/ml,
Sigma) and UPO (0.2 mg/ml) in citrate buffer were added for
30 min and the reaction was stopped with 25% H2SO4.
Absorbance was read at 490 nm. For IgG1/IgG2a ELISA the
following antibodies were used: biotin anti-mouse IgG1 (diluted
1:10000 in blocking buffer) and biotin anti-mouse IgG2a (diluted
1:6250 in blocking buffer), both from Jackson Immunoresearch
(generous gift of Dr. J. Quandt). In this case, after washing and
before adding the substrate, streptavidin-HRP was added (diluted
in blocking buffer 1:1000, Jackson Immunoresearch).
Direct intracellular staining, mixed assay and cell transfers
Sterile Brefeldin A was purchased from Sigma and 250 mg were
injected intravenously in mice at day 4 post EAE induction [44].
Six hours later mice were euthanized and spleen and inguinal
lymph nodes were harvested. Cells were prepared and stained to
CD11b+CD11c+ isolated from the spleens of cHV-68 EAE mice (grey shaded histograms) or a naı̈ve EAE mice (open histograms) at day 4 post EAE
induction. (D) CD11b+CD11c+ isolated from both cHV-68 EAE and naı̈ve EAE mice at day 4 post EAE were transferred into naı̈ve mice. Twenty-four
hours later EAE was induced in both groups. At day 14–16 post EAE induction (mean clinical score between 2 and 3 for both groups), brains and
spinal cords were harvested and the production of IFN-c and IL-17 by CD4 T cells in the CNS of mice that received CD11b+CD11c+ cells from cHV-68
EAE mice (black bars) or from naive EAE mice (open bars) was assessed after in-vitro restimulation with PMA and ionomycin. Results obtained from
the spinal cords are shown, a similar trend was observed in the brain. Three separate experiments with 5 mice/group. Data were analyzed with t-test:
* p,0.05.
doi:10.1371/journal.ppat.1002715.g008
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detect IL-6, IL-12, TNF-a, IFN-c and IL-10 as described above.
Intracellular staining was performed without any further ex-vivo
restimulation.
For mixed assay, spleens and inguinal lymph nodes were
harvested at day 4 post EAE induction. A single cell suspension
was prepared and stained with anti-CD11c and anti-CD11b
antibodies (see above for details). CD11c+ CD11b+ cells were
sorted with a FACSAria cell sorter (BD Biosciences). CD4 T cells
from 2D2 mice were isolated from spleens with a CD4 T cells
negative selection kit following manufacturer’s instructions
(STEMCELL technologies). Isolated CD11b+CD11c+ (26104/
well) and 2D2 CD4 T cells (56105/well) were seeded on a 24 well
plate in RPMI, 10% FBS and Pen/Strep (all from GIBCO) with
or without 10 or 100 mM MOG peptide. After 72 hours, T cells
were restimulated with PMA, ionomycin and GolgiPlug and
stained for CD4 and IFN-c as described above.
For cell transfers, CD11b+CD11c+ cells were sorted as
described above. Each mouse received 100,000 cells intra
peritoneally. EAE was induced 24 hours post-transfer.
Statistical analysis
Two-way ANOVA analysis followed by Bonferroni’s post test
was used to compare EAE scores, Kaplan-Meier analysis was used
to compare survival curves and unpaired Student’s t-test or Mann-
Whitney U-test were used for all the other analyses (GraphPad
Prism).
Supporting Information
Figure S1 cHV-68 EAE mice show increased amount of
immune cells infiltrations in the spinal cords. Mice were
infected with cHV-68 (right panels) or MEM only (left panels).
Five weeks p.i. EAE was induced. At day 28 post EAE induction
mice were perfused and spinal cords were harvested, fixed in
formalin and paraffin embedded (similar results obtained at day 15
post EAE induction). Cross-sections were stained with H&E (upper
panels) and luxol fast blue (lower panels). Representative pictures
of three separate experiments. Scale bar = 100 mm.
(TIF)
Figure S2 cHV-68 EAE mice show increased T cell
expression of IFN-c accompanied by IL-17 suppression
after MOG restimulation. Mice were infected with cHV-68
(black bars, shaded histograms) or MEM only (open bars, open
histograms). Five weeks p.i. EAE was induced. At day 14–16 post
EAE induction (mean clinical score of 3 for cHV-68 EAE mice,
EAE mice were harvested at the same time) mice were perfused,
brains (left panels) and spinal cords (right panels) were harvested
and processed to isolate immune infiltrates that were restimulated
for 24 hours with 100 mM MOG peptide before performing FACS
intra cellular staining (A) Percentages of infiltrating CD3+ CD4+
IFN-c+ lymphocytes. (B) Percentage of infiltrating CD3+ CD8+
IFN-c lymphocytes (EAE CD8 infiltrations were not enough to
perform FACS). (C) CD3+ CD4+ IL-17+ lymphocytes. Two
experiments with 6 mice/group. Data were analyzed with t-test:
* p,0.05.
(TIF)
Figure S3 cHV-68 EAE mice show increased levels of
pro-inflammatory cytokines in the serum. Mice were
infected i.p. with cHV-68 (black bars) or MEM only (open bars).
Five weeks p.i., EAE was induced. At day 10 (A) and 15 (B) post
EAE induction blood was harvested through a cardiac puncture
and the levels of cytokines were evaluated using BD Cytometric
Bead Array kits. Three-two separate experiment for each time
point with 3–6 mice/group. Data were analyzed with t-test:
*** p,0.001; ** p,0.01, * p,0.05.
(TIF)
Figure S4 cHV-68 EAE mice show increased levels of
IFN-c in CNS supernatants. Mice were infected i.p. with
cHV-68 (black bars) or MEM only (open bars). Five weeks p.i.,
EAE was induced. At day 14–16 post EAE induction (mean score
of 3 for cHV-68 EAE mice, EAE mice were harvested at the same
time), mice were perfused and brains and spinal cords were
homogenized and the supernatants were analyzed for the presence
of cytokines. Levels of cytokines were evaluated using BD
Cytometric Bead Array kits. Two separate experiments with 3–6
mice/group. Data were analyzed with t-test: * p,0.05.
(TIF)
Figure S5 cHV-68 EAE mice show increased levels of
CXCR3 on splenic T cells. Mice were infected i.p. with cHV-
68 (black bars) or MEM only (open bars). Five weeks p.i., EAE was
induced. At day 15 post EAE induction, spleens were harvested
and the levels of CXCR3 were assessed through FACS analysis.
The histograms show the numbers of CD4+CXCR3+ cells (left
panel) or CD8+CXCR3+ cells (right panel) One experiment with
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